Millendo Therapeutics Inc

Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development and discovery of small molecule drugs for treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.

Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST” Tempest to Trade on Nasdaq Public Markets Under Ticker “TPST”

Tempest and Millendo Announce Stockholder Approval of Merger

NEW YORK, April 27, 2021 /PRNewswire/ -- If you own Millendo shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http://www.weisslawllp.com/MLND/ Or please contact: Joshua Rubin, Esq. WeissLaw LLP1500 Broadway, 16th Floor New York, NY  10036 (212) 682-3025(888) 593-4771 stockinfo@weisslawllp.com WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Millendo Therapeutics, Inc. ("Millendo" or the "Company") (NASDAQ: MLND) in connection with the proposed merger of the Company with privately-held clinical-stage oncology company Tempest Therapeutics, Inc. ("Tempest").

SHAREHOLDER ALERT: WeissLaw LLP Investigates Millendo Therapeutics, Inc.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Millendo Therapeutics, Inc. (NasdaqGS: MLND) (“the Company”) with Tempest Therapeutics, Inc. pursuant to which Millendo shareholders are expected to only own approximately 18.5% of the combined company, subject to adjustments. KSF is seeking to determine whether the merger and the process that led to it are

MILLENDO INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Millendo Therapeutics, Inc. - MLND

NEW YORK, April 2, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Millendo Therapeutics, Inc. ("MLND" or the "Company") ( MLND ) relating to its proposed merger with Tempest Therapeutics, Inc. Under the terms of the agreement, MLND shareholders are expected to own 18.5% of the combined company. The investigation focuses on whether Millendo Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Millendo Therapeutics, Inc. - MLND

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Millendo Therapeutics, Inc. (NASDAQ: MLND) and Tempest Therapeutics, Inc. is fair to Millendo shareholders. Upon completion of the merger, Millendo shareholders are expected to own approximately 18.5% of the combined company while pre-merger Tempest stockholders will own approximately 81.5% of the combined company. Halper Sadeh encourages Millendo shareholders to click here to

Millendo Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Millendo Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – MLND

The stock price of Millendo Therapeutics Inc (NASDAQ: MLND) fell by over 10% pre-market. This is why it happened.

MLND Stock Price Falls Over 10% Pre-Market: Why It Happened

Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction. The combined company will operate under the Tempest Therapeutics moniker under ticker 'TPST,' focusing on advancing Tempest's oncology pipeline of small molecule candidates.

Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger

SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics and Tempest Therapeutics announce a proposed merger agreement.

Tempest and Millendo Announce Proposed Merger Agreement

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces updates on its pipeline and business, including its Phase 1 study of MLE-301 for the treatment of vasomotor symptoms.

Millendo Therapeutics Provides Pipeline and Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics announces operating and financial results for the quarter ended September 30, 2020.

Millendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results

China Green Agriculture

UTStarcom Holdings

There are some investors who buy stocks that are trading below their liquidation value because they believe they can achieve impressive gains from their investments after the market has reassessed the share prices up to near or above the liquidation value. Should the company fail, these shareholders would in theory still be able to earn a profit due to a difference between the liquidation value and purchasing price.

3 Net Net Working Capital Stocks to Have a Look At

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist that is being developed for the treatment of VMS, commonly known as hot flashes and night sweats, in menopausal women.

Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Participate in September Investor Conferences

Millendo Therapeutics to Participate in September Investor Conferences

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

Millendo Therapeutics Reports Second Quarter 2020 Operating and Financial Results

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Millendo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Investors need to pay close attention to Millendo (MLND) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Millendo (MLND) Stock?

As of late, it has definitely been a great time to be an investor in Millendo Therapeutics.

Will Millendo Continue to Surge Higher?

Millendo Therapeutics: A Forgotten Biotech With Strong Potential

Millendo Therapeutics Inc’s (NASDAQ: MLND) lead asset livoletide is in a registrational study (ZEPHYR) for the treatment of PraderWilli Syndrome (PWS), which is an unmet need, according to Wedbush.

Millendo's Lead Asset Could Address Unmet PWS Need, Wedbush Says

It’s not that unusual in the world of biotech and emerging medtech to run across companies that have previously never been heard of or covered.

News for Millendo Therapeutics Inc Stock (MLND)